Hyderabad-based generic injectables manufacturer and CDMO partner serving the US, Europe, RoW and India.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3.6k | 5.9k | 7.1k | 7.9k | 8.7k | 9.1k | 9.5k | 10.3k |
| Borrowings | 5 | 5 | 5 | 4 | 372 | 314 | 302 | 284 |
| Other Liabilities | 435 | 588 | 671 | 814 | 1.5k | 1.7k | 1.9k | 1.9k |
| Total Liabilities | 4.1k | 6.5k | 7.8k | 8.8k | 10.6k | 11.2k | 11.8k | 12.5k |
| AssetsFixed Assets | 968 | 954 | 1.5k | 1.6k | 3.9k | 4.1k | 4.4k | 4.5k |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 209 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2.9k | 5.2k | 6.0k | 7.0k | 6.4k | 6.9k | 7.2k | 7.7k |
| Total Assets | 4.1k | 6.5k | 7.8k | 8.8k | 10.6k | 11.2k | 11.8k | 12.5k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 701 | 605 | 791 | 364 | 997 | 915 | 1.0k |
| Cash from Investing | -761 | -1.5k | -999 | 1.2k | -1.7k | 1.7k | 138 |
| Cash from Financing | -7 | 1.2k | 35 | 15 | -799 | -433 | -417 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (39.3×) and current (39.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 9.6% growth and a 39× exit, ₹2449 only delivers your return if you pay ₹1,652. The price is currently baking in 18% growth.
EPS grows 9.6%/yr for 5 years, then fades to 6% over 2, exits at 39×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 9.6% | 68.35 |
| FY28 | 9.6% | 74.91 |
| FY29 | 9.6% | 82.10 |
| FY30 | 9.6% | 89.98 |
| FY31 | 9.6% | 98.62 |
| FY32 | 7.8% ·fade | 106.31 |
| FY33 | 6.0% ·fade | 112.69 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.